

CCR2
Metabolic Modulating
Protein-Cytokine Fusion
A52R deletion
TK deletion

FIG. 1



2500
2000
1500
1000
500
0
Tumor Volume (mm3)
0
5
10
15
20
25
30
35
Day post treatment
1
2
3
1 VFB
2 WR.TK-
3 MMC

FIG. 2A



Survival to Day 28
Probability of Survival
100
50
0
0
10
20
30
Time
1
2
3
1 MMC
2 WR.TK-
3 Vehicle

FIG. 2B



LLC Day 28
Tumor Volume (mm3)
1500
1000
500
0
Vehicle
WR.TK-
MMC
**** p< 0.00´ MMC vs WR.TK-

FIG. 2C



Copies/mg tumor
1.5×10^8
1.0×10^8
5.0×10^7
0.0
WR.TK-
MMC

FIG. 2D



2500
2000
1500
1000
500
0
Tumor Volume (mm³)
0 2 4 6 8 10 12 14 16 18
Day post treatment
1
2
3
1 Vehicle
2 MMC
3 MMC Imm.

FIG. 3A



10⁸
10⁷
10⁶
10⁵
PFU/mg
MMC
MMC immunized

FIG. 3B



Renca (Day 14 post treatment)
Tumor Volume (mm3)
800
600
400
200
0
VFB
WR.TK-
MMC

FIG. 4



No Tumor-all
Genomes/mg
100000
10000
1000
100
10
1
NT 202N Liver
NT 428N Liver
NT 202N Spleen
NT 428N Spleen
NT 202N Brain
NT 428N Brain
NT 202N Heart
NT 428N Heart
NT 202N Kidney
NT 428N Kidney
NT 202N GI Tract
NT 428N GI Tract
NT 202N Bone Marrow
NT 428N Bone Marrow
NT 202N Lungs
NT 428N Lungs

FIG. 5A



LLC- all
Genomes/mg
10^8
10^7
10^6
10^5
10^4
10^3
10^2
10^1
10^0
LLC 202N Liver
LLC 428N Liver
LLC 202N Spleen
LLC 428N Spleen
LLC 202N Brain
LLC 428N Brain
LLC 202N Heart
LLC 428N Heart
LLC 202N Kidney
LLC 428N Kidney
LLC 202N GI Tract
LLC 428N GI Tract
LLC 202N Bone Marrow
LLC 428N Bone Marrow
LLC 202N Lungs
LLC 428N Lungs
LLC 202N Tumor
LLC 428N Tumor

FIG. 5B